ide-cel 早期复发后 BCMA 靶向双特异性抗体治疗结局不佳：一项法国真实世界研究
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.
63.4分
★★★☆☆
站内排序·非疗效
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
FRONTIER PAPERS
前沿论文 6
条件筛选 · 已选 4 项 · 共 6 条展开收起
多发性骨髓瘤中 CAR-T 或 BiTE 治疗的患者选择：每位患者应选择哪种治疗？
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
62.5分
★★★☆☆
站内排序·非疗效
双特异性抗体在多发性骨髓瘤中的演进
The evolution of bispecific antibodies in multiple myeloma.
46.3分
★★★☆☆
站内排序·非疗效
无限可能以及如何利用它们？最佳治疗顺序是什么？
Endless possibilities and how to exploit them? What is the optimal treatment sequence?
43.3分
★★☆☆☆
站内排序·非疗效
多发性骨髓瘤治疗前线的革命：寻找治愈方法的经验与挑战
Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure.
37.6分
★★☆☆☆
站内排序·非疗效
多发性骨髓瘤靶向免疫治疗新前沿的潜力抗原
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
31.3分
★☆☆☆☆
站内排序·非疗效
共 6 条